|
|
|
| Biosafety Risks of Synthetic Biology Related to Human Immunity and The Countermeaseures |
FU Meng-meng1,SU Dan-dan2,ZUO Kun-lan3,WU Zong-zhen3,LI Si-si4,XU Yan-long5,LIU Huan3,6,**( ) |
1 Beijing Science Communication Development and Research Center, Beijing 100101, China
2 Renmin Hospital of Wuhan University, Wuhan 430072, China
3 School of Humanities and Social Sciences, University of Science and Technology of China, Hefei 230026, China
4 Office of Laboratory Management, Chinese Center for Disease Control and Prevention, Beijing 102206, China
5 College of Humanities, University of Chinese Academy of Sciences, Beijing 100049, China
6 Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China |
|
|
|
Abstract Human immune-related synthetic biology has always been one of the hot spots in the international biomedical field, which has shown great application potential in such fields as immunotherapy for critical diseases and preventive medicine. Moreover, human immune-related synthetic biology and biological safety will increasingly become an important health research topic for science and technology to benefit human welfare. This cutting-edge research field will also affect the overall national security and the future fate of mankind. By focusing on the analysis of possible biosafety risk factors in the field of synthetic biology related to human immunity, the research was conducted from five aspects: the impact of microorganisms on immune function, immunosuppression, immune overreaction, autoimmune response and human genomic immunity, and the biosafety issues related to synthetic biology were proposed and the corresponding strategies were proposed as safeguard measures for the scientific and technological innovation and development of biosafety and synthetic biotechnology in the field of human health.
|
|
Received: 13 November 2022
Published: 04 July 2023
|
|
|
|
|
| [1] |
Inda M E, Lu T K. Microbes as biosensors. Annual Review of Microbiology, 2020, 74: 337-359.
doi: 10.1146/annurev-micro-022620-081059
pmid: 32660390
|
|
|
| [2] |
Kang M, Choe D, Kim K, et al. Synthetic biology approaches in the development of engineered therapeutic microbes. International Journal of Molecular Sciences, 2020, 21(22): 8744.
doi: 10.3390/ijms21228744
|
|
|
| [3] |
van Spronsen F J, Blau N, Harding C, et al. Phenylketonuria. Nature Reviews Disease Primers, 2021, 7(1): 1-19.
doi: 10.1038/s41572-020-00234-1
|
|
|
| [4] |
Isabella V M, Ha B N, Castillo M J, et al. Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. Nature Biotechnology, 2018, 36(9): 857-864.
doi: 10.1038/nbt.4222
pmid: 30102294
|
|
|
| [5] |
Hamady Z Z R, Scott N, Farrar M D, et al. Xylan-regulated delivery of human keratinocyte growth factor-2 to the inflamed colon by the human anaerobic commensal bacterium Bacteroides ovatus. Gut, 2010, 59(4): 461-469.
doi: 10.1136/gut.2008.176131
pmid: 19736360
|
|
|
| [6] |
Mimee M, Nadeau P, Hayward A, et al. An ingestible bacterial-electronic system to monitor gastrointestinal health. Science, 2018, 360(6391): 915-918.
doi: 10.1126/science.aas9315
pmid: 29798884
|
|
|
| [7] |
Zhang L, Morgan R A, Beane J D, et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin Cancer Res, 2015, 21(10): 2278-2288.
doi: 10.1158/1078-0432.CCR-14-2085
pmid: 25695689
|
|
|
| [8] |
Yew C H T, Gurumoorthy N, Nordin F, et al. Integrase deficient lentiviral vector: prospects for safe clinical applications. PeerJ, 2022, 10: e13704.
doi: 10.7717/peerj.13704
|
|
|
| [9] |
Rajendran L, Paolicelli R. Microglia-mediated synapse loss in alzheimer’s disease. The Journal of Neuroscience, 2018, 38: 2911-2919.
doi: 10.1523/JNEUROSCI.1136-17.2017
|
|
|
| [10] |
Maes M E, Colombo G, Schulz R, et al. Targeting microglia with lentivirus and AAV: recent advances and remaining challenges. Neuroscience Letters, 2019, 707: 134310.
doi: 10.1016/j.neulet.2019.134310
|
|
|
| [11] |
Guo Q, Zhang J, Zheng Z S, et al. Lentivirus-mediated microRNA-26a-modified neural stem cells improve brain injury in rats with cerebral palsy. Journal of Cellular Physiology, 2020, 235(2): 1274-1286.
doi: 10.1002/jcp.29043
pmid: 31264214
|
|
|
| [12] |
Guo Z S, Lu B F, Guo Z B, et al. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. Journal for ImmunoTherapy of Cancer, 2019, 7(1): 6.
doi: 10.1186/s40425-018-0495-7
pmid: 30626434
|
|
|
| [13] |
Shukarev G, Callendret B, Luhn K, et al. A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks. Human Vaccines & Immunotherapeutics, 2017, 13(2): 266-270.
|
|
|
| [14] |
Iwakuma T, Cui Y, Chang L J. Self-inactivating lentiviral vectors with U3 and U5 modifications. Virology, 1999, 261(1): 120-132.
pmid: 10441560
|
|
|
| [15] |
Guerin J L, Gelfi J, Boullier S, et al. Myxoma virus leukemia-associated protein is responsible for major histocompatibility complex class I and Fas-CD 95 down-regulation and defines scrapins, a new group of surface cellular receptor abductor proteins. Journal of Virology, 2002, 76(6): 2912-2923.
doi: 10.1128/JVI.76.6.2912-2923.2002
|
|
|
| [16] |
Liszewski M K, Leung M K, Hauhart R, et al. Smallpox inhibitor of complement enzymes (SPICE): dissecting functional sites and abrogating activity. The Journal of Immunology, 2009, 183(5): 3150-3159.
doi: 10.4049/jimmunol.0901366
|
|
|
| [17] |
Hong M H, Clubb J D, Chen Y Y. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell, 2020, 38(4): 473-488.
doi: 10.1016/j.ccell.2020.07.005
pmid: 32735779
|
|
|
| [18] |
Pehlivan K C, Duncan B B, Lee D W. CAR-T cell therapy for acute lymphoblastic leukemia: transforming the treatment of relapsed and refractory disease. Current Hematologic Malignancy Reports, 2018, 13(5): 396-406.
doi: 10.1007/s11899-018-0470-x
pmid: 30120708
|
|
|
| [19] |
Jin Y J, Dong Y, Zhang J, et al. The toxicity of cell therapy: mechanism, manifestations, and challenges. Journal of Applied Toxicology, 2021, 41(5): 659-667.
doi: 10.1002/jat.4100
pmid: 33241595
|
|
|
| [20] |
Ahmed S, Ahmed M Z, Rafique S, et al. Recent approaches for downplaying antibiotic resistance: molecular mechanisms. BioMed Research International, 2023, 2023: 1-27.
|
|
|
| [21] |
Hoshiga F, Yoshizaki K, Takao N, et al. Modification of T2 phage infectivity toward Escherichia coli O157: H7 via using CRISPR/Cas9. FEMS Microbiology Letters, 2019, 366(4): fnz041.
|
|
|
| [22] |
Federici S, Nobs S P, Elinav E. Phages and their potential to modulate the microbiome and immunity. Cellular & Molecular Immunology, 2021, 18(4): 889-904.
|
|
|
| [23] |
Dabrowska K, Górski A, Abedon S T. Bacteriophage pharmacology and immunology. Bacteriophages. Cham: Springer, 2021: 295-339.
|
|
|
| [24] |
Liang S, Latchman Y, Buhlmann J, et al. Regulation of PD-1, PD-L1, and PD-L 2 expression during normal and autoimmune responses. European Journal of Immunology, 2003, 33(10): 2706-2716.
doi: 10.1002/(ISSN)1521-4141
|
|
|
| [25] |
Sharpe A H, Pauken K E. The diverse functions of the PD1 inhibitory pathway. Nature Reviews Immunology, 2018, 18(3): 153-167.
doi: 10.1038/nri.2017.108
pmid: 28990585
|
|
|
| [26] |
周静文, 何明基, 练辉, 等. 免疫检查点抑制剂PD-1免疫相关不良反应的临床分析. 介入放射学杂志, 2021, 30(1): 29-33.
|
|
|
| [26] |
Zhou J W, He M J, Lian H, et al. Clinical analysis of immune-related adverse events of PD-1 immune checkpoint inhibitors. Journal of Interventional Radiology, 2021, 30(1): 29-33.
|
|
|
| [27] |
Sieiro Santos C, Álvarez Castro C, Moriano Morales C, et al. Anti-TNF-α-induced lupus syndrome. Zeitschrift Für Rheumatologie, 2021, 80(5): 481-486.
doi: 10.1007/s00393-021-00983-8
|
|
|
| [28] |
ChavarríaMiranda A, Hernández Lain A, Toldos González O, et al. Immune-mediated necrotizing myopathy after treatment with adalimumab in a patient with HLA-B 27 ankylosing spondylitis. Neurologia (Barcelona, Spain), 2020, 36(8): 631-632.
|
|
|
| [29] |
Carapetis J R, Beaton A, Cunningham M W, et al. Acute rheumatic fever and rheumatic heart disease. Nature Reviews Disease Primers, 2016, 2(1): 1-24.
|
|
|
| [30] |
Ramos-Casals M, Brito-Zerón P, Soto M J, et al. Autoimmune diseases induced by TNF-targeted therapies. Best Practice & Research Clinical Rheumatology, 2008, 22(5): 847-861.
|
|
|
| [31] |
Neradová A, Stam F, van den Berg J G, et al. Etanercept-associated SLE with lupus nephritis. Lupus, 2009, 18(7): 667-668.
doi: 10.1177/0961203308100560
pmid: 19433471
|
|
|
| [32] |
Reyes L M, Estrada J L, Wang Z Y, et al. Creating class I MHC-null pigs using guide RNA and the Cas9 endonuclease. The Journal of Immunology, 2014, 193(11): 5751-5757.
doi: 10.4049/jimmunol.1402059
|
|
|
| [33] |
刘珊, 方姝煜. 基因编辑治疗原发性免疫缺陷病. 中国当代儿科杂志, 2021, 23(7): 743-748.
|
|
|
| [33] |
Liu S, Fang S Y. Gene editing for the treatment of primary immunodeficiency disease. Chinese Journal of Contemporary Pediatrics, 2021, 23(7): 743-748.
|
|
|
| [34] |
Zhang J P, Yu X P, Guo P, et al. Satellite subgenomic particles are key regulators of adeno-associated virus life cycle. Viruses, 2021, 13(6): 1185.
doi: 10.3390/v13061185
|
|
|
| [35] |
Adams D, Gonzalez-Duarte A, O’Riordan W D, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine, 2018, 379(1): 11-21.
doi: 10.1056/NEJMoa1716153
|
|
|
| [36] |
Ratner M. Patients with porphyria bask in sunlight of FDA approval. Nature Biotechnology, 2019, 37(12): 1390-1391.
doi: 10.1038/s41587-019-0347-0
pmid: 31796929
|
|
|
| [37] |
Scott L J, Keam S J. Lumasiran: first approval. Drugs, 2021, 81(2): 277-282.
doi: 10.1007/s40265-020-01463-0
pmid: 33405070
|
|
|
| [38] |
赵晴, 陈广洁. siRNA在自身免疫病治疗中的研究进展. 现代免疫学, 2012, 32(6):519-522.
|
|
|
| [38] |
Zhao Q, Chen G J. Research progress of siRNA in the treatment of autoimmune diseases. Current Immunology, 2012, 32(6):519-522.
|
|
|
| [39] |
曲泽鹏, 陈沫先, 曹朝辉, 等. 合成微生物群落研究进展. 合成生物学, 2020, 1(6): 621-634.
doi: 10.12211/2096-8280.2020-012
|
|
|
| [39] |
Qu Z P, Chen M X, Cao C H, et al. Research advances in synthetic microbial communities. Synthetic Biology Journal, 2020, 1(6): 621-634.
doi: 10.12211/2096-8280.2020-012
|
|
|
| [40] |
宁峻涛, 邹诗施, 左锟澜, 等. 合成生物活性物质的生物安全风险和应对策略研究. 中国生物工程杂志, 2023, 43(2-3): 180-189.
|
|
|
| [40] |
Ning J T, Zou S S, Zuo K L, et al. Biosafety risks and countermeasures of active substance in synthesis biology. China Biotechnology, 2023, 43(2-3): 180-189.
|
|
|
| [41] |
冀朋. 合成生物学的哲学基础问题研究. 武汉:华中科技大学, 2021.
|
|
|
| [41] |
Ji P. Research on philosophical foundation of synthetic biology. Wuhan:Huazhong University of Science and Technology, 2021.
|
|
|
| [42] |
潘婷婷, 张娟. 腺相关病毒载体工程研究. 生物化工, 2020, 6(4):156-159, 162
|
|
|
| [42] |
Pan T T, Zhang J. Recent advances in engineering adeno-associated virus. Shengwu Huagong, 2020, 6(4):156-159, 162
|
|
|
| [43] |
李洋, 申晓林, 孙新晓, 等. CRISPR基因编辑技术在微生物合成生物学领域的研究进展. 合成生物学, 2021, 2(1):106-120.
doi: 10.12211/2096-8280.2020-039
|
|
|
| [43] |
Li Y, Shen X L, Sun X X, et al. Advances of CRISPR gene editing in microbial synthetic biology. Synthetic Biology Journal, 2021, 2(1):106-120.
doi: 10.12211/2096-8280.2020-039
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
